Biogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow BIIB
Biogen Inc. (BIIB) EPS (diluted)
Biogen Inc.'s EPS (diluted) for fiscal 2025 was $8.79, down 21.4% from $11.18 in fiscal 2024. Over the twelve months to 30 June 2026 it was $5.65. Over the past ten years it has ranged from $7.97 (fiscal 2023) to $31.42 (fiscal 2019); the current reading is higher than 18% of that period. Biogen Inc. ranks 6th of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $8.79 | (21.38%) |
| FY2024 | $11.18 | 40.28% |
| FY2023 | $7.97 | (61.81%) |
| FY2022 | $20.87 | 100.67% |
| FY2021 | $10.40 | (58.06%) |
| FY2020 | $24.80 | (21.07%) |
| FY2019 | $31.42 | 45.60% |
| FY2018 | $21.58 | 81.04% |
| FY2017 | $11.92 | (29.59%) |
| FY2016 | $16.93 | 10.37% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.66 | (69.30%) |
| Mar 2026 | $2.15 | — |
| Dec 2025 | −$0.33 | — |
| Sep 2025 | $3.17 | (26.79%) |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AMGN Amgen Inc. compare | $16.09 |
| AZN AstraZeneca PLC compare | $6.69 |
| BIIB Biogen Inc. | $5.65 |
| BMY Bristol Myers Squibb Company compare | $4.54 |
| NVO Novo Nordisk A/S compare | $4.09 |
| GSK GSK PLC Sponsored ADR compare | $3.20 |
| SNY Sanofi compare | $1.91 |
| PFE Pfizer Inc. compare | $0.76 |
| GILD Gilead Sciences, Inc. compare | −$2.67 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on BIIB
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement